Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis

• Autores principales: Donger Zhang (Autor), Xia Li (Autor), Jing Ding (Autor), Xiatong Ke (Autor), Wenpei Ding (Autor), Yinan Ren (Autor), He Xu (Autor), Hongchao Li (Autor), Aixia Ma (Autor), Wenxi Tang (Autor)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2021-07-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Introduction: China has ~6 million patients with active epilepsy every year, around 60% of whom suffer from partial-onset seizures. Perampanel (PER) is a novel anti-epileptic drug for partial-onset seizures. PER has been included in the latest Chinese National Reimbursement Drug List (NRDL) in 2020....